Clean Yield Group Grows Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Clean Yield Group increased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 4,108.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,010 shares of the medical research company’s stock after purchasing an additional 986 shares during the quarter. Clean Yield Group’s holdings in Edwards Lifesciences were worth $75,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Cooper Financial Group raised its holdings in Edwards Lifesciences by 2.8% in the 4th quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock worth $479,000 after purchasing an additional 175 shares in the last quarter. Wedmont Private Capital raised its position in shares of Edwards Lifesciences by 5.0% in the 4th quarter. Wedmont Private Capital now owns 8,348 shares of the medical research company’s stock worth $613,000 after acquiring an additional 398 shares in the last quarter. Brookstone Capital Management raised its position in shares of Edwards Lifesciences by 12.7% in the 4th quarter. Brookstone Capital Management now owns 5,484 shares of the medical research company’s stock worth $406,000 after acquiring an additional 616 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST boosted its position in shares of Edwards Lifesciences by 6.7% during the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after purchasing an additional 300,000 shares in the last quarter. Finally, Czech National Bank grew its stake in Edwards Lifesciences by 4.2% in the fourth quarter. Czech National Bank now owns 127,881 shares of the medical research company’s stock worth $9,467,000 after purchasing an additional 5,166 shares during the period. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their target price for the company from $82.00 to $90.00 in a report on Monday, December 16th. Canaccord Genuity Group boosted their price objective on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a research note on Thursday, December 5th. Stifel Nicolaus raised their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research note on Thursday, December 5th. Morgan Stanley reissued an “equal weight” rating and issued a $70.00 price target on shares of Edwards Lifesciences in a research report on Friday, October 11th. Finally, Jefferies Financial Group lowered Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their price objective for the company from $85.00 to $70.00 in a research report on Wednesday, September 18th. Sixteen equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $79.40.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 37,500 shares of company stock valued at $2,508,350. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE:EW traded down $1.66 during mid-day trading on Monday, hitting $71.76. 3,260,834 shares of the company traded hands, compared to its average volume of 3,822,875. The stock’s fifty day moving average price is $71.64 and its 200-day moving average price is $71.92. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The firm has a market cap of $42.32 billion, a price-to-earnings ratio of 10.35, a price-to-earnings-growth ratio of 3.61 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm’s revenue was up 8.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.59 EPS. Research analysts anticipate that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.